Regulus Therapeutics’ (RGLS) “Buy” Rating Reaffirmed at HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $9.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 268.85% from the company’s previous close.

Several other equities research analysts have also issued reports on RGLS. Canaccord Genuity Group dropped their price target on Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, March 19th. Leerink Partnrs reiterated an “outperform” rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. Wells Fargo & Company upped their price target on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 13th. StockNews.com assumed coverage on shares of Regulus Therapeutics in a research note on Tuesday, April 16th. They set a “sell” rating for the company. Finally, SVB Leerink initiated coverage on Regulus Therapeutics in a report on Monday, March 18th. They set an “outperform” rating and a $6.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Regulus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Regulus Therapeutics Trading Down 7.9 %

Shares of Regulus Therapeutics stock traded down $0.21 during trading on Monday, hitting $2.44. The stock had a trading volume of 541,093 shares, compared to its average volume of 2,260,311. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79. The firm has a market cap of $159.72 million, a price-to-earnings ratio of -1.56 and a beta of 1.59. The business’s 50-day moving average is $2.30 and its 200 day moving average is $1.68.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). As a group, equities analysts expect that Regulus Therapeutics will post -0.52 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of RGLS. Vivo Capital LLC purchased a new position in shares of Regulus Therapeutics during the first quarter valued at approximately $14,400,000. FMR LLC raised its stake in Regulus Therapeutics by 32.4% during the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 716,000 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in Regulus Therapeutics by 5.3% during the third quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 11,701 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.